Influence of Transporter Polymorphisms on Drug Disposition and Response: A Perspective From the International Transporter Consortium

Autor: Aleksandra Galetin, Deanna J. Brackman, Landry K. Kamdem, Lei Zhang, Kathleen M. Giacomini, Rebecca Blanchard, Elizabeth A. Ennis, Sook Wah Yee, Yuichi Sugiyama

Publikováno v: Yee, S W, Brackman, D J, Ennis, E A, Sugiyama, Y, Kamdem, L K, Blanchard, R, Galetin, A, Zhang, L & Giacomini, K M 2018, ' Influence of Transporter Polymorphisms on Drug Disposition and Response : A Perspective From the International Transporter Consortium ', Clinical Pharmacology and Therapeutics . https://doi.org/10.1002/cpt.1098
Clinical pharmacology and therapeutics, vol 104, iss 5

Advances in genomic technologies have led to a wealth of information identifying genetic polymorphisms in membrane transporters, specifically how these polymorphisms affect drug disposition and response. This review describes the current perspective

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6fe3505ae50d815f26acf42de958cdf0
https://doi.org/10.1002/cpt.1098

Drug- and patient-related factors are the strongest predictors of endocrine therapy adherence in breast cancer patients

Autor: Sophia Tilley, Mariam F Haji-Hersi, Landry K. Kamdem, Nathan Lamb, Caleb A Shelton

Publikováno v: Journal of Oncology Pharmacy Practice. :107815522110208

Purpose Medication non-adherence to treatment regimens can severely impact the mortality of patients afflicted with breast cancer.The purpose of this study was to identify factors that contribute to non-adherence to endocrine therapy in breast cancer

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d6b499c87c432840e2c4daf900a4ad81
https://doi.org/10.1177/10781552211020805

COX2 induction: a mechanism of endocrine breast cancer resistance?

Autor: Landry K. Kamdem, Michael A. Murphy, Brandi L. Clark

Publikováno v: Breast cancer research and treatment. 165(2)

Urine prostaglandin E2 (PGE2) levels have shown to be a risk factor of breast cancer, and the use of nonsteroidal anti-inflammatory drugs (NSAIDs) is known to be beneficial in preventing breast cancer risk and/or recurrence with or without aromatase

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::945522acac7b4d3feb44a957b64b7147
https://pubmed.ncbi.nlm.nih.gov/28639029

In vitro and in vivo oxidative metabolism and glucuronidation of anastrozole

Autor: Stacie Jeter, Bryan A. Ward, Yong Liu, Zeruesenay Desta, Jacqueline Ramírez, David A. Flockhart, Mark J. Ratain, Evan T. Ogburn, Susan Kadlubar, Karineh Shahverdi, Landry K. Kamdem, Vered Stearns

Publikováno v: British Journal of Clinical Pharmacology. 70:854-869

WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT • Anastrozole is primarily cleared by hepatic metabolism via oxidative and conjugating enzymes. WHAT THIS STUDY ADDS • Anastrozole is oxidized to hydroxyanastrozole mainly by CYP3A4/5 and glucuronidated to

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::743df6282f09ccfd9fc6f78ba6443407
https://doi.org/10.1111/j.1365-2125.2010.03791.x

Clinical implications ofCYP3Apolymorphisms

Autor: Landry K. Kamdem, Leszek Wojnowski

Publikováno v: Expert Opinion on Drug Metabolism & Toxicology. 2:171-182

Due to their enormous substrate spectrum CYP3A4, -3A5 and -3A7 constitute the most important drug-metabolising enzyme subfamily in humans. CYP3As are expressed predominantly, but not exclusively, in the liver and intestine, where they participate in

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5df31ee549e19afb4ca1af2118020ed0
https://doi.org/10.1517/17425255.2.2.171